|
|
Previous Article | Table of Contents | Next Article 
Blood, Vol. 93 No. 1 (January 1), 1999:
pp. 341-349
Cytokine-Specific Activation of Distinct Mitogen-Activated
Protein Kinase Subtype Cascades in Human Neutrophils
Stimulated by Granulocyte Colony-Stimulating Factor,
Granulocyte-Macrophage Colony-Stimulating Factor, and Tumor Necrosis
Factor-
By
Kenichi Suzuki,
Masayuki Hino,
Fumihiko Hato,
Noriyuki Tatsumi, and
Seiichi Kitagawa
From the Departments of Physiology and Clinical Hematology, Osaka
City University Medical School, Osaka, Japan.
 |
ABSTRACT |
To clarify the differences of the signaling pathways used by
granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), and tumor necrosis factor- (TNF), we investigated activation of mitogen-activated protein kinase
(MAPK) subtype cascades in human neutrophils stimulated by these
cytokines. G-CSF exclusively tyrosine-phosphorylated extracellular signal-regulated kinase (ERK). GM-CSF
tyrosine-phosphorylated ERK strongly and p38 MAPK weakly, whereas TNF
tyrosine-phosphorylated p38 MAPK strongly and ERK weakly. Consistent
with these findings, MEK, an upstream kinase of ERK, was phosphorylated
by G-CSF, GM-CSF, and TNF, whereas MKK3/MKK6, an upstream kinase of p38
MAPK, was phosphorylated by GM-CSF and TNF, but not by G-CSF. The
potency of these cytokines to phosphorylate ERK and MEK was GM-CSF > G-CSF > TNF, whereas that to phosphorylate p38 MAPK and MKK3/MKK6 was TNF > GM-CSF. C-Jun amino-terminal kinase (JNK) was not
tyrosine-phosphorylated by any cytokine despite the existence of JNK
proteins in human neutrophils, whereas it was tyrosine-phosphorylated
by TNF in undifferentiated and all-trans retinoic acid-differentiated
HL-60 cells. Increased phosphorylation of ERK or p38 MAPK was detected within 1 to 5 minutes after stimulation with each cytokine and was
dependent on the concentrations of cytokines used. MEK inhibitor (PD98059) reduced tyrosine phosphorylation of ERK, but not p38 MAPK,
induced by G-CSF, GM-CSF, or TNF. GM-CSF- or TNF-induced superoxide
(O2 ) release was inhibited by p38 MAPK
inhibitor (SB203580) in a dose-dependent manner, suggesting the
possible involvement of p38 MAPK in GM-CSF- or TNF-induced
O2 release. The results indicate that G-CSF,
GM-CSF, and TNF activate the overlapping but distinct MAPK subtype
cascades in human neutrophils and suggest that the differential
activation of ERK and p38 MAPK cascades may explain the differences of
the effects of these cytokines on human neutrophil functions.
© 1999 by The American Society of Hematology.
 |
INTRODUCTION |
VARIOUS FUNCTIONS of mature human
neutrophils are known to be activated or potentiated by hematopoietic
growth factors or inflammatory cytokines, including granulocyte
colony-stimulating factor (G-CSF), granulocyte-macrophage
colony-stimulating factor (GM-CSF), and tumor necrosis factor-
(TNF).1-3 Activation or potentiation of mature neutrophil
functions by these cytokines may contribute not only to augmenting the
host-defense against invading microorganisms, but also to increasing
the tissue damage at the inflammatory sites. However, the mechanisms by
which these cytokines activate or prime mature neutrophils are largely
unknown.
Our previous studies show that there are some similarities in the
characteristics of G-CSF-, GM-CSF-, and TNF-mediated activation or
priming of human neutrophils1-3; ie, all these cytokines
potentiate the responses triggered by receptor-mediated agonists such
as N-formyl-methionyl-leucyl-phenylalanine (FMLP), but not by phorbol myristate acetate (PMA), a direct activator of protein kinase C, and do
not by themselves stimulate any changes in cytoplasmic free
Ca2+ and transmembrane potential. All of these cytokines
induce intracellular alkalinization and tyrosine phosphorylation of a
42-kD protein.4 On the other hand, there are definite
differences among the effects of these cytokines on human neutrophils.
For example, superoxide (O2 ) release in
suspended human neutrophils is stimulated by GM-CSF or TNF, but not by
G-CSF.1-3 NF- B pathway in human neutrophils is activated
by TNF, but not by G-CSF or GM-CSF.5 These previous studies
suggest that these cytokines may not only share the common signaling
pathways, but also use the cytokine-specific distinct signaling
pathways in human neutrophils.
The mitogen-activated protein kinase (MAPK) cascade is a major
signaling system that is shared by various types of
cells.6,7 In mammalian cells, there are at least three MAPK
subtypes; ie, extracellular signal-regulated kinase (ERK), p38 MAPK,
and c-Jun amino-terminal kinase (JNK). The ERK cascade is activated in
response to signals from receptor tyrosine kinases, hematopoietic
growth factor receptors, or some heterotrimeric G-protein-coupled
receptors and appears to mediate signals promoting cell proliferation
or differentiation. The p38 MAPK and JNK cascades are activated in response to heat shock, hyperosmolarity, UV irradiation, protein synthesis inhibitors, or inflammatory cytokines and appear to be
involved in the cell responses to stresses. Each MAPK subtype is
activated by phosphorylation on threonine and tyrosine residues by an
upstream dual-specificity kinase and phosphorylate substrates on serine
or threonine adjacent to proline residues. Activation of the distinct
MAPK subtype cascade is dependent on the types of cells and the stimuli
used, and the functional role of each MAPK subtype may be different
according to the types of cells.
Activation of the MAPK cascade is not restricted to immature cells, and
this cascade is also activated in terminally differentiated cells such
as neutrophils, suggesting that the MAPK cascade also plays an
important role in some functions of terminally differentiated mature
cells. We previously reported that tyrosine phosphorylation of a 42-kD
protein, possibly a MAPK subtype, is closely associated with the
priming effects of G-CSF, GM-CSF, and TNF on human
neutrophils.4 By using the immunoprecipitation with
specific antibodies against MAPK subtypes, we have recently
demonstrated that the distinct MAPK subtype in human neutrophils is
exclusively tyrosine-phosphorylated by GM-CSF and TNF.8 ERK
was exclusively tyrosine-phosphorylated by GM-CSF, whereas p38 MAPK was
exclusively tyrosine-phosphorylated by TNF.8 However,
controversial results are reported about activation or tyrosine
phosphorylation of MAPK subtypes in human neutrophils stimulated by
cytokines. For example, it has been reported that TNF induces tyrosine
phosphorylation of ERK in adherent, but not suspended, human
neutrophils9; GM-CSF, but not TNF, activates ERK in
human neutrophils10-12; and both TNF and GM-CSF induce tyrosine phosphorylation of p38 MAPK.13 In addition, it remains to be determined whether a tyrosine-phosphorylated 42-kD
protein in human neutrophils stimulated by G-CSF also belongs to the
MAPK family. In this report, we investigated phosphorylation of MAPK
subtypes (ERK, p38 MAPK, and JNK) and upstream kinases of these MAPK
subtypes (MAPK/ERK kinase [MEK] and MAPK kinase-3 or 6 [MKK3/MKK6])
in human neutrophils stimulated by G-CSF, GM-CSF, and TNF. The
comparative studies show that G-CSF, GM-CSF, and TNF activate the
overlapping but distinct MAPK subtype cascades in human neutrophils;
ie, G-CSF exclusively tyrosine-phosphorylated ERK; GM-CSF
tyrosine-phosphorylated ERK strongly and p38 MAPK weakly; TNF
tyrosine-phosphorylated p38 MAPK strongly and ERK weakly; and JNK was
not tyrosine-phosphorylated by any cytokine. The results suggest that
the differential activation of the MAPK subtype cascades may explain
the differences of the effects of these cytokines on human neutrophil
functions and p38 MAPK may be involved in activation of
O2 release.
 |
MATERIALS AND METHODS |
Reagents.
Highly purified recombinant human G-CSF, GM-CSF, and TNF produced by
Escherichia coli were provided by Kirin Brewery Co Ltd (Tokyo,
Japan), Schering-Plough Co Ltd (Osaka, Japan), and Dainippon Pharmaceutical Co Ltd (Osaka, Japan), respectively. The specific activity of TNF was 3 × 106 U/mg protein. Endotoxin
contamination of each preparation was less than 100 pg/mg protein.
Cytochrome c type III, superoxide dismutase, and all-trans
retinoic acid (ATRA) were purchased from Sigma Chemical (St Louis, MO);
Conray was purchased from Mallinckrodt (St Louis, MO); and Ficoll was
purchased from Pharmacia Fine Chemicals (Piscataway, NJ). PD98059 (MEK
inhibitor) and rabbit polyclonal antibodies against
Ser217/221-phosphorylated MEK1/MEK2,
Ser189/207-phosphorylated MKK3/MKK6, ERK1/ERK2,
Tyr204-phosphorylated ERK1/ERK2, JNK/SAPK,
Thr183/Tyr185-phosphorylated JNK/SAPK, p38
MAPK, and Thr180/Tyr182-phosphorylated p38 MAPK
were purchased from New England Biolabs (Beverly, MA). SB203580 (p38
MAPK inhibitor) was provided by SmithKline Beecham Pharmaceuticals
(King of Prussia, PA). The enhanced chemiluminescence (ECL) Western
blotting system was purchased from Amersham (Arlington Heights, IL).
Cell culture.
Human myelogenous leukemia cell line HL-60 cells were grown in
RPMI-1640 medium supplemented with 10% heat-inactivated fetal calf
serum, penicillin (100 U/mL), and streptomycin (100 µg/mL). For
induction of differentiation of HL-60 to granulocytic cells, cells were
seeded at 2 × 105 cells/mL and grown in the presence
or absence of 1 µmol/L ATRA for 4 days.14
Preparation of cells.
Cultured HL-60 cells were harvested after 4 days of cultivation with or
without ATRA, washed three times, and suspended in Hanks' balanced
salt solution (HBSS). Human neutrophils were prepared from healthy
adult donors as described,1 using dextran sedimentation, centrifugation with Conray-Ficoll, and hypotonic lysis of contaminated erythrocytes. Neutrophil fractions were suspended in HBSS and contained
more than 98% neutrophils.
Western blotting.
Human neutrophils (1 × 107/mL) suspended in HBSS
were prewarmed for 10 minutes at 37°C and were then
stimulated with cytokines for 1 to 40 minutes at 37°C. The
reactions were terminated by rapid centrifugation, and the
pellets were frozen in liquid nitrogen after aspiration of the
supernatant. The cell-pellets were resuspended in ice-cold
solution containing 50 mmol/L HEPES (pH 7.4), 1% Triton X-100, 2 mmol/L sodium orthovanadate, 100 mmol/L sodium fluoride, 1 mmol/L EDTA,
1 mmol/L EGTA, 1 mmol/L phenylmethylsulfonyl fluoride, 100 µg/mL
aprotinin, and 10 µg/mL leupeptin and were lysed for 60 minutes at
4°C. After rapid centrifugation, the supernatant was mixed 1:1 with
2× sample buffer (4% sodium dodecyl sulfate [SDS], 20%
glycerol, 10% mercaptoethanol, and a trace amount of bromophenol blue
dye in 125 mmol/L Tris-HCl, pH 6.8), heated at 100°C for 5 minutes,
and then frozen at 80°C until use. Samples were subjected to
10% SDS gel electrophoresis. After electrophoresis, proteins were
electrophoretically transferred from the gel onto a nitrocellulose
membrane in a buffer containing 25 mmol/L Tris, 192 mmol/L glycine, and
20% methanol at 2 mA/cm2 for 4 hours at 25°C. Residual
binding sites on the membrane were blocked by incubating the membrane
in Tris-buffered saline (pH 7.6) containing 0.1% Tween 20 and 5%
nonfat dry milk for 2 hours at 25°C. The blots were washed in
Tris-buffered saline containing 0.1% Tween 20 (TBST) and then
incubated with appropriate antibody overnight at 4°C. After washing
three times with TBST, the membrane was incubated with anti-rabbit IgG
antibody conjugated with horseradish peroxidase, and the antibody
complexes were visualized by the ECL detection system as directed by
the manufacturer.
Determination of O2 release.
O2 was assayed by superoxide-dismutase
inhibitable reduction of ferricytochrome c, as
described.15 The cell suspension in HBSS was added to a
polypropylene tube (Falcon #2063; Falcon Labware, Becton
Dickinson, Franklin Lakes, NJ) containing 100 µmol/L ferricytochrome c with or without superoxide dismutase (200 U/mL) to obtain a final volume of 0.2 mL. The final cell concentration was 2 × 105 cells/0.2 mL. The reaction mixture was preincubated in
the presence or absence of SB203580 (0.01 to 10 µmol/L) for 20 minutes at 37°C, and thereafter GM-CSF (5 ng/mL) or TNF (100 U/mL)
was added. After incubation for 3 hours at 37°C, the reduction of
ferricytochrome c was measured at 550 nm, with a reference
wavelength at 540 nm.
Statistical analysis.
The Student's t-test was used to determine statistical
significance.
 |
RESULTS |
ERK1 and ERK2 were tyrosine-phosphorylated by G-CSF, GM-CSF, and TNF.
Human neutrophils in suspension were stimulated with G-CSF (50 ng/mL),
GM-CSF (5 ng/mL), or TNF (100 U/mL) for 10 minutes at 37°C, and
tyrosine phosphorylation of ERK1 and ERK2 was analyzed by
immunoblotting using polyclonal antibody against
tyrosine-phosphorylated ERK1 and ERK2. As shown in
Fig 1, both ERK1 and ERK2 were strongly tyrosine-phosphorylated by GM-CSF with predominant phosphorylation of
ERK2, in agreement with previous reports.10-12 Increased
tyrosine phosphorylation of ERK1 and ERK2 was also detected in
suspended human neutrophils stimulated by G-CSF and TNF, although it
was much weaker than that induced by GM-CSF. ERK2 was predominantly tyrosine-phosphorylated by G-CSF and TNF. In TNF-stimulated
neutrophils, an additional band was always detected just below the ERK2
band by this antibody, although it is unknown whether this band is related to ERK family or not (Fig 1; see also Figs 4 and 7).

View larger version (41K):
[in this window]
[in a new window]
| Fig 1.
Phosphorylation of ERK1, ERK2, and p38 MAPK in human
neutrophils stimulated by G-CSF, GM-CSF, or TNF. Cells were stimulated
with G-CSF (50 ng/mL), GM-CSF (5 ng/mL), or TNF (100 U/mL) for 10 minutes at 37°C. Phosphorylation of ERK1, ERK2, and p38 MAPK was
analyzed by immunoblotting using antibody against phosphorylated form
of each protein (upper panel). The equal loading of proteins onto each
lane was confirmed by immunoblotting using antibody that recognizes
both phosphorylated and unphosphorylated forms of ERK1/ERK2 or p38 MAPK
(lower panel). The cell lysates equivalent to 3.8 × 106
cells were loaded onto each lane. The results shown are representative
of seven independent experiments. In this experiment, the exposure time
was somewhat prolonged to determine whether G-CSF was able to
phosphorylate p38 MAPK, which is responsible for higher baseline level
of p38 MAPK phosphorylation as compared with that shown in Figs 3, 4,
and 7.
|
|
Tyrosine phosphorylation of ERK1 and ERK2 was dependent on the
concentrations of G-CSF, GM-CSF, and TNF used as stimuli. When neutrophils were stimulated with G-CSF for 10 minutes, a significant increase of tyrosine phosphorylation of ERK1 and ERK2 was detected at
0.5 ng/mL G-CSF and maximal stimulation was obtained at 5 ng/mL G-CSF
(Fig 2). G-CSF-induced tyrosine
phosphorylation of ERK1 and ERK2 was rapid and already detected at 1 minute after stimulation with 50 ng/mL G-CSF, and the maximal level was
observed at 3 minutes, followed by a gradual decrease of the level. The
time-courses of tyrosine phosphorylation of ERK1 and ERK2 were similar
to each other (Fig 2).

View larger version (52K):
[in this window]
[in a new window]
| Fig 2.
Phosphorylation of ERK1, ERK2, and p38 MAPK in human
neutrophils stimulated by G-CSF. Cells were stimulated with indicated
concentrations of G-CSF for 10 minutes at 37°C or stimulated with
50 ng/mL G-CSF for indicated periods at 37°C. Phosphorylation of
ERK1, ERK2 (upper 2 panels), and p38 MAPK (lower panel) was analyzed by
immunoblotting using antibody against phosphorylated form of each
protein. The cell lysates equivalent to 2.7 × 106 cells
were loaded onto each lane. The results shown are representative of
five independent experiments. In this experiment, the exposure time was
somewhat prolonged to determine whether G-CSF was able to phosphorylate
p38 MAPK, which is responsible for higher baseline level of p38 MAPK
phosphorylation as compared with that shown in Figs 3, 4, and 7.
|
|
When neutrophils were stimulated with GM-CSF for 10 minutes, a
significant increase of tyrosine phosphorylation of ERK1 and ERK2 was
detected at 0.5 ng/mL GM-CSF. No further increase of tyrosine
phosphorylation of ERK1 and ERK2 was observed when the concentrations
of GM-CSF were increased up to 50 ng/mL
(Fig 3). GM-CSF-induced tyrosine
phosphorylation of ERK1 and ERK2 was rapid and already detected at 1 minute after stimulation with 5 ng/mL GM-CSF, and the maximal level was
observed at 3 minutes, followed by gradual decrease of the level. The
time-courses of tyrosine phosphorylation of ERK1 and ERK2 were similar
to each other (Fig 3).

View larger version (44K):
[in this window]
[in a new window]
| Fig 3.
Phosphorylation of ERK1, ERK2, and p38 MAPK in human
neutrophils stimulated by GM-CSF. Cells were stimulated with indicated
concentrations of GM-CSF for 10 minutes at 37°C or stimulated with
5 ng/mL GM-CSF for indicated periods at 37°C. Phosphorylation of
ERK1, ERK2, (upper 2 panels) and p38 MAPK (lower 2 panels) was analyzed
by immunoblotting using antibody against phosphorylated form of each
protein. The cell lysates equivalent to 1.9 × 106 cells
were loaded onto each lane. The results shown are representative of
three independent experiments.
|
|
When neutrophils were stimulated with TNF for 10 minutes, a significant
increase of tyrosine phosphorylation of ERK1 and ERK2 was detected at 1 U/mL TNF. No further increase of tyrosine phosphorylation of ERK1 and
ERK2 was observed when the concentrations of TNF were increased up to
1,000 U/mL (Fig 4). TNF-induced tyrosine
phosphorylation of ERK1 and ERK2 was clearly detected at 3 minutes
after stimulation with 100 U/mL TNF, and the maximal level was observed
at 5 minutes, followed by a gradual decrease of the level (Fig 4). The
weak phosphorylation of ERK in TNF-stimulated neutrophils may be
responsible for our previous failure to detect tyrosine phosphorylation
of ERK in these cells by means of immunoprecipitation.8 The
comparative studies showed that the potency of these cytokines to
induce tyrosine phosphorylation of ERK1/ERK2 was GM-CSF > G-CSF > TNF (Fig 1). These findings are consistent with the previous report by
Raines et al16 that the potency of GM-CSF to induce
activation of MAPK is greater than that of G-CSF. The equal loading of
proteins onto each lane in each experiment was confirmed by
immunoblotting using antibody, which recognizes both phosphorylated and
unphosphorylated forms of ERK1/ERK2 (Fig 1; data not shown for Figs 2,
3, and 4). The retarded mobility of part of ERK2 observed in
GM-CSF-stimulated cells (Fig 1, lower panel) may reflect strong
tyrosine-phosphorylation of ERK2 by GM-CSF and is consistent with
previous reports.11,12

View larger version (38K):
[in this window]
[in a new window]
| Fig 4.
Phosphorylation of ERK1, ERK2, and p38 MAPK in human
neutrophils stimulated by TNF. Cells were stimulated with indicated
concentrations of TNF for 10 minutes at 37°C or stimulated with 100 U/mL TNF for indicated periods at 37°C. Phosphorylation of ERK1,
ERK2 (upper 2 panels), and p38 MAPK (lower 2 panels) was analyzed by
immunoblotting using antibody against phosphorylated form of each
protein. The cell lysates equivalent to 3 × 106 cells
were loaded onto each lane. The results shown are representative of
three independent experiments.
|
|
A p38 MAPK was tyrosine-phosphorylated by GM-CSF and TNF, but not by
G-CSF.
Human neutrophils were stimulated with G-CSF (50 ng/mL), GM-CSF (5 ng/mL), or TNF (100 U/mL) for 10 minutes at 37°C, and tyrosine phosphorylation of p38 MAPK was analyzed by immunoblotting using polyclonal antibody against tyrosine-phosphorylated p38 MAPK. As shown
in Fig 1, p38 MAPK was significantly tyrosine-phosphorylated by GM-CSF
and TNF, but not by G-CSF. G-CSF-induced increase in tyrosine
phosphorylation of p38 MAPK was not detected even when the incubation
time with G-CSF (50 ng/mL) was prolonged up to 40 minutes (Fig 2). The
level of tyrosine phosphorylation of p38 MAPK was sometimes, but not
always, reduced transiently in the early periods (within 10 minutes)
after G-CSF stimulation (Fig 1).
When neutrophils were stimulated with GM-CSF for 10 minutes at
37°C, a significant increase of tyrosine phosphorylation of p38
MAPK was detected at 0.5 ng/mL GM-CSF and maximal stimulation was
obtained at 5 ng/mL (Fig 3). As observed with G-CSF stimulation, the
level of tyrosine phosphorylation of p38 MAPK was sometimes, but
not always, reduced transiently in the early periods (within 3 minutes)
after GM-CSF stimulation (Fig 3). A significant increase of tyrosine
phosphorylation of p38 MAPK was detected at 5 minutes after GM-CSF
stimulation, and the maximal level was observed at 5 to 10 minutes,
followed by slight decrease of the level (Fig 3). The weak
phosphorylation of p38 MAPK in GM-CSF-stimulated neutrophils may be
responsible for our previous failure to detect tyrosine phosphorylation
of p38 MAPK in these cells by means of immunoprecipitation.8
When neutrophils were stimulated with TNF for 10 minutes, a remarkable
increase of tyrosine phosphorylation of p38 MAPK was already detected
at 1 U/mL TNF. No further increase of tyrosine phosphorylation of p38
MAPK was observed when the concentrations of TNF were increased up to
1,000 U/mL (Fig 4). TNF-induced tyrosine phosphorylation of p38 MAPK
was rapid and already detected at 1 minute after stimulation, and the
maximal level was observed at 5 to 10 minutes, followed by a gradual
decrease of the level (Fig 4). The comparative studies showed that the
potency of these cytokines to induce tyrosine phosphorylation of p38
MAPK was TNF > GM-CSF (Fig 1). The equal loading of proteins onto
each lane in each experiment was confirmed by immunoblotting using
antibody, which recognizes both phosphorylated and unphosphorylated
forms of p38 MAPK (Fig 1; data not shown for Figs 2, 3, and 4).
No tyrosine phosphorylation of JNK in human neutrophils stimulated by
G-CSF, GM-CSF, and TNF.
Human neutrophils were stimulated with G-CSF (50 ng/mL), GM-CSF (5 ng/mL), or TNF (100 U/mL) for 10 minutes at 37°C, and tyrosine phosphorylation of JNK was analyzed by immunoblotting using polyclonal antibody against tyrosine-phosphorylated JNK. As shown in
Fig 5, no significant increase of tyrosine
phosphorylation of JNK was detected in neutrophils stimulated by G-CSF,
GM-CSF, or TNF. G-CSF-, GM-CSF-, or TNF-induced increase in tyrosine
phosphorylation of JNK was not detected even when the incubation time
with each cytokine was prolonged up to 40 minutes (data not shown). The immunoblotting using antibody, which recognizes both phosphorylated and
unphosphorylated forms of JNK, showed that two JNK isoforms (JNK1 and
JNK2) were detected in human neutrophils (Fig 5). Thus, it appears that
in human neutrophils JNK is not tyrosine-phosphorylated by any cytokine
despite the existence of JNK proteins.

View larger version (43K):
[in this window]
[in a new window]
| Fig 5.
Phosphorylation of JNK in human neutrophils,
undifferentiated HL-60 cells, and ATRA-differentiated HL-60 cells
stimulated by G-CSF, GM-CSF, or TNF. Cells were stimulated with G-CSF
(50 ng/mL), GM-CSF (5 ng/mL), or TNF (100 U/mL) for 10 minutes at
37°C. Phosphorylation of JNK was analyzed by immunoblotting using
antibody against phosphorylated form of JNK (upper panel). The
existence of JNK protein was analyzed by immunoblotting using antibody,
which is produced by immunizing rabbits with a full-length JNK2 fusion
protein and recognizes both phosphorylated and unphosphorylated forms
of JNK (lower panel). Total extracts from human embryonic kidney 293 cells prepared with UV light treatment were used as
phosphorylation-positive controls. The cell lysates equivalent to 4.7 × 106 neutrophils, 1.9 × 106
undifferentiated HL-60 cells, or 1.9 × 106 differentiated
HL-60 cells were loaded onto each lane. The results shown are
representative of four independent experiments.
|
|
Tyrosine phosphorylation of JNK in undifferentiated and
ATRA-differentiated HL-60 cells stimulated by TNF.
No tyrosine phosphorylation of JNK was also observed in human
neutrophils stimulated by other agonists including FMLP (0.1 µmol/L),
PMA (100 ng/mL), and ionomycin (1 µmol/L; data not shown). However,
Rane et al17 have recently reported that FMLP induced tyrosine phosphorylation and activation of JNK in HL-60 cells differentiated by dimethyl sulfoxide (DMSO). This difference might be
attributed to the difference of cells used. We then analyzed tyrosine
phosphorylation of JNK by using undifferentiated and ATRA-differentiated HL-60 cells. As shown in Fig 5, significant tyrosine phosphorylation of JNK was detected in undifferentiated and
differentiated HL-60 cells stimulated by TNF, but not by G-CSF or
GM-CSF. Stimulation of KG-1 cells, another myelogenous leukemia cell
line, with TNF also resulted in strong tyrosine phosphorylation of two
JNK isoforms (data not shown). These findings indicate that, in
contrast to normal human neutrophils, differentiated HL-60 cells retain
the signaling pathway for tyrosine phosphorylation of JNK.
Effects of G-CSF, GM-CSF, and TNF on phosphorylation of MEK1/MEK2 and
MKK3/MKK6.
ERK and p38 MAPK are reported to be activated by the distinct signaling
cascades.6,7 ERK1 and ERK2 are phosphorylated and activated
by MEK1/MEK2, which is phosphorylated and activated by upstream
serine/threonine kinases such as Raf and MEK kinase. On the other hand,
p38 MAPK is phosphorylated and activated by MKK3/MKK6, which is also
phosphorylated and activated by upstream serine/threonine kinases.
However, it appears that these signaling cascades are not applicable to
all types of cells. In fact, it has been reported that erythropoietin
and interleukin-3 (IL-3) activate p38 MAPK in FDC-P2 cells, a murine
hematopoietic progenitor cell line, without activating
MKK3/MKK6.18 We then studied the effects of G-CSF, GM-CSF,
and TNF on phosphorylation of MEK1/MEK2 and MKK3/MKK6 in human
neutrophils by using antibodies against serine-phosphorylated MEK1/MEK2
and serine-phosphorylated MKK3/MKK6. As shown in
Fig 6, stimulation of human neutrophils
with G-CSF (50 ng/mL), GM-CSF (5 ng/mL), or TNF (100 U/mL) for 5 minutes at 37°C resulted in increased phosphorylation of MEK1/MEK2,
and the potency of this effect was GM-CSF > G-CSF > TNF. The equal loading of proteins onto each lane was confirmed by immunoblotting using antibody, which recognizes both phosphorylated and
unphosphorylated forms of ERK1/ERK2 (data not shown). This finding
supports the idea that MEK1/MEK2 is an upstream kinase for ERK1 and
ERK2. Similarly, significant increase of phosphorylation of MKK3/MKK6
was detected in neutrophils stimulated by GM-CSF or TNF, but not by
G-CSF, and the potency of this effect was TNF > GM-CSF (Fig
6). The equal loading of proteins onto each lane was confirmed by
immunoblotting using antibody, which recognizes both phosphorylated and
unphosphorylated forms of p38 MAPK (data not shown). Thus, this finding
supports the idea that MKK3/MKK6 is an upstream kinase for p38 MAPK.

View larger version (62K):
[in this window]
[in a new window]
| Fig 6.
Phosphorylation of MEK1/MEK2 and MKK3/MKK6 in human
neutrophils stimulated by G-CSF, GM-CSF, or TNF. Cells were stimulated
with G-CSF (50 ng/mL), GM-CSF (5 ng/mL), or TNF (100 U/mL) for 5 minutes at 37°C. Phosphorylation of MEK1/MEK2 and MKK3/MKK6 was
analyzed by immunoblotting using antibody against phosphorylated form
of each protein. The cell lysates equivalent to 3 × 106
cells were loaded onto each lane. The results shown are representative
of three independent experiments.
|
|
Effect of PD98059 on tyrosine phosphorylation of ERK1, ERK2, and p38
MAPK induced by G-CSF, GM-CSF, and TNF.
To clarify further the possible participation of MEK1/MEK2 in tyrosine
phosphorylation of ERK1/ERK2, we studied the effect of PD98059, a
potent inhibitor of MEK,19 on tyrosine phosphorylation of
ERK1/ERK2 in human neutrophils stimulated by G-CSF, GM-CSF, and TNF. As
shown in Fig 7, tyrosine phosphorylation of
ERK1 and ERK2 induced by G-CSF (50 ng/mL), GM-CSF (5 ng/mL), or TNF
(100 U/mL) was markedly reduced by the pretreatment of cells with
PD98059 (100 µmol/L) for 30 minutes at 37°C. Under the same
conditions, tyrosine phosphorylation of p38 MAPK induced by GM-CSF (5 ng/mL) or TNF (100 U/mL) was hardly reduced by PD98059. The equal
loading of proteins onto each lane was confirmed by immunoblotting
using antibody, which recognizes both phosphorylated and
unphosphorylated forms of ERK1/ERK2 or p38 MAPK (data not shown).

View larger version (55K):
[in this window]
[in a new window]
| Fig 7.
Effect of PD98059 on tyrosine phosphorylation of ERK1,
ERK2, and p38 MAPK in human neutrophils stimulated by G-CSF, GM-CSF, or
TNF. Cells were pretreated with PD98059 (100 µmol/L) for 30 minutes
at 37°C and thereafter stimulated with G-CSF (50 ng/mL), GM-CSF (5 ng/mL), or TNF (100 U/mL) for 10 minutes at 37°C. Phosphorylation
of ERK1, ERK2, and p38 MAPK was analyzed by immunoblotting using
antibody against phosphorylated form of each protein. The cell lysates
equivalent to 2.8 × 106 cells were loaded onto each lane.
The results shown are representative of three independent
experiments.
|
|
Effect of SB203580 on O2 release
stimulated by GM-CSF and TNF.
Tyrosine phosphorylation of p38 MAPK in human neutrophils was induced
by GM-CSF and TNF, but not by G-CSF, and the potency of this effect was
TNF > GM-CSF (Figs 1 through 4). These findings are consonant with
our previous observations that O2
release in suspended human neutrophils is induced by GM-CSF and TNF,
but not by G-CSF,1-3 and the potency of this effect is TNF > GM-CSF20 (Table 1). These
findings raise the possibility that p38 MAPK may be involved in
O2 release stimulated by GM-CSF and TNF.
We then studied the effect of SB203580, a potent inhibitor of p38
MAPK,21 on O2 release in
human neutrophils stimulated by GM-CSF or TNF. As shown in Table 1,
when cells were pretreated with SB203580 (0.01 to 10 µmol/L) for 20 minutes at 37°C, GM-CSF- or TNF-induced
O2 release was inhibited by SB203580 in
a dose-dependent manner.
 |
DISCUSSION |
The present experiments show that stimulation of human neutrophils with
G-CSF, GM-CSF, and TNF results in activation of the distinct MAPK
subtype cascades in a cytokine-specific manner. G-CSF exclusively
activates the ERK cascade; GM-CSF activates the ERK cascade strongly
and the p38 MAPK cascade weakly; TNF activates the p38 MAPK cascade
strongly and the ERK cascade weakly; and the JNK cascade is not
activated by any cytokine. The differential activation of MAPK subtype
cascades may explain the differences of the effects of these cytokines
on human neutrophil functions.
G-CSF, GM-CSF, and TNF all induced tyrosine phosphorylation of ERK1 and
ERK2 and phosphorylation of MEK1/MEK2, and the potency of these
cytokines to induce phosphorylation of ERK1/ERK2 and MEK1/MEK2 was
GM-CSF > G-CSF > TNF. In addition, tyrosine phosphorylation of ERK1
and ERK2 was markedly inhibited by PD98059, a potent inhibitor of MEK.
These findings suggest that the signals provoked by the binding of
G-CSF, GM-CSF, and TNF to their receptors converge to activation of
MEK, which in turn phosphorylates and activates ERK1 and ERK2.
Activation of this cascade appears to be independent of activation of
the p38 MAPK cascade, because (1) G-CSF selectively induced tyrosine
phosphorylation of ERK1 and ERK2 and did not induce tyrosine
phosphorylation of p38 MAPK; (2) ERK1/ERK2 and p38 MAPK were
differentially tyrosine-phosphorylated by GM-CSF and TNF (ie, the
potency of tyrosine phosphorylation of ERK1/ERK2 was GM-CSF > TNF,
whereas that of p38 MAPK was TNF > GM-CSF); (3) PD98059 markedly
reduced tyrosine phosphorylation of ERK1 and ERK2 induced by GM-CSF or
TNF, whereas it hardly reduced tyrosine phosphorylation of p38 MAPK
induced by GM-CSF or TNF; and (4) tyrosine phosphorylation of p38 MAPK
and phosphorylation of MKK3/MKK6 were induced by GM-CSF and TNF, but
not by G-CSF, and the potency of these cytokines to induce
phosphorylation of p38 MAPK and MKK3/MKK6 was TNF > GM-CSF. These
findings also support the concept that GM-CSF and TNF, but not G-CSF,
activate the MKK3/MKK6-p38 MAPK cascade in human neutrophils, as
observed in other types of cells stimulated by appropriate
agonists.6,7 However, these findings contrast with the
observations obtained from FDC-P2 cells, a murine hematopoietic cell
line, in which erythropoietin and IL-3 appear to activate p38 MAPK
through a kinase other than MKK3/MKK6.18 The aberrant
signaling pathways, which developed in FDC-P2 cells, might explain
these differences.
In regard to tyrosine phosphorylation or activation of JNK in human
neutrophils, controversial results are reported. It has been reported
that FMLP does not activate JNK in normal human neutrophils,22 whereas a recent report shows that FMLP
activates JNK in mature HL-60 cells differentiated by
DMSO.17 In the present experiments, we could not detect
tyrosine phosphorylation of JNK in normal human neutrophils stimulated
by various agonists (G-CSF, GM-CSF, TNF, FMLP, PMA, and ionomycin),
despite the existence of JNK proteins. On the other hand, JNK was
tyrosine-phosphorylated in undifferentiated and ATRA-differentiated
HL-60 cells stimulated by TNF, but not by G-CSF or GM-CSF. We also
observed tyrosine phosphorylation of JNK in KG-1 cells, another
myelogenous leukemia cell line, stimulated by TNF. Taken together,
these findings suggest that the signaling pathway from TNF receptors to
JNK exists in certain myeloid leukemia cell lines and still exists in
granulocytic HL-60 cells differentiated by ATRA or DMSO, but this
pathway does not work in normal mature human neutrophils. It is
conceivable that certain signaling molecules mediating the signal
transduction from TNF receptors to JNK may be defective in mature human
neutrophils. Although it has been reported that JNK is activated in
certain murine cell lines stimulated by G-CSF,23 we could
not detect G-CSF-induced tyrosine phosphorylation of JNK in HL-60
cells or in leukemic cells obtained from some patients with acute
myelogenous leukemia (data not shown).
Our previous study shows that stimulation of human neutrophils with
G-CSF, GM-CSF, and TNF results in tyrosine phosphorylation of a 42-kD
protein, which may be associated with the priming effect of these
cytokines on O2 release.4
The present experiments show that the tyrosine-phosphorylated 42-kD
protein in human neutrophils stimulated by G-CSF is ERK1/ERK2, but not
p38 MAPK and JNK, and ERK2 is predominantly tyrosine-phosphorylated by
G-CSF. In considering that G-CSF never stimulates
O2 release in human
neutrophils,1,2 these findings indicate that ERK1 and ERK2
are unlikely to be involved in triggering of O2 release, but rather suggest that ERK1
and ERK2 may be involved in other functions, such as the priming effect
or the inhibition of apoptosis.24 Consistent with this is
the finding that PD98059, a MEK inhibitor, does not inhibit the release
of O2 in human neutrophils stimulated by
FMLP, which can activate the MEK-ERK cascade.25,26 It has
been also demonstrated that cyclic AMP dissociates ERK activation from
the oxidative burst in human neutrophils stimulated by FMLP or
PMA.27 In myeloid cells, the activation of ERK cascade has
been proposed to be associated with proliferative, but not
nonproliferative, responses to G-CSF.28 However, the
present study suggests that the ERK1/ERK2 cascade also plays a role in
functional responses of mature human neutrophils to G-CSF. The present
findings are consistent with the previous report by Colotta et
al29 that stimulation of human neutrophils with G-CSF,
GM-CSF, or TNF results in induction of c-fos mRNA expression,
because ERK is known to be involved in induction of c-fos mRNA
expression in various types of cells.30
One remarkable difference among the effects of G-CSF, GM-CSF, and TNF
on human neutrophil functions is that both GM-CSF and TNF stimulate
O2 release directly in suspended human
neutrophils, whereas G-CSF does not.1-3 The potency for
this effect is TNF > GM-CSF.20 These findings are
consonant with the ability of these cytokines to stimulate tyrosine
phosphorylation of p38 MAPK. In addition, increased tyrosine
phosphorylation of p38 MAPK, which was detected within 1 to 5 minutes
after stimulation with GM-CSF or TNF (Figs 3 and 4), preceded or
occurred concomitantly with O2 release
induced by each cytokine.2,3 These findings and the
inhibition of GM-CSF- and TNF-induced
O2 release by SB203580, a p38 MAPK
inhibitor, when taken together, suggest that p38 MAPK plays a role in
O2 release stimulated by GM-CSF and TNF.
It has been also reported that p38 MAPK may be involved in
O2 release in human neutrophils
stimulated by FMLP, but not by platelet activating
factor.22 The inability of G-CSF to stimulate
O2 release in human neutrophils may be
attributed to the inability of G-CSF to activate p38 MAPK.
The present experiments show that G-CSF, GM-CSF, and TNF activate the
distinct MAPK subtypes (ERK1/ERK2 and p38 MAPK) in human neutrophils
and suggest that the differential activation of ERK1/ERK2 and p38 MAPK
may partly explain the differences of the effects of these cytokines on
human neutrophil functions, as evidenced by the close relationship
between activation of the p38 MAPK cascade and
O2 release stimulated by G-CSF, GM-CSF,
and TNF. The JNK cascade appears not to work in mature neutrophils.
Further investigations are required to clarify the roles of each MAPK
subtype cascade in cytokine-induced activation of human neutrophil
functions as well as hematopoietic precursor cells.
 |
ACKNOWLEDGMENT |
The authors thank Dr A. Yuo (International Medical Center of Japan,
Tokyo, Japan) for valuable discussions.
 |
FOOTNOTES |
Submitted March 23, 1998;
accepted August 31, 1998.
Supported by Grants-in-Aid from the Ministry of Education, Science and
Culture, Japan.
The publication costs of this
article were defrayed in part by
page charge payment. This article
must therefore be hereby marked
"advertisement"
in accordance with 18 U.S.C. section
1734 solely to indicate this fact.
Address reprint requests to Seiichi Kitagawa, MD, Department of
Physiology, Osaka City University Medical School, Asahi-machi,
Abeno-ku, Osaka 545-8585, Japan.
 |
REFERENCES |
1.
Yuo A, Kitagawa S, Ohsaka A, Ohta M, Miyazono K, Okabe T, Urabe A, Saito M, Takaku F:
Recombinant human granulocyte colony-stimulating factor as an activator of human granulocytes: Potentiation of responses triggered by receptor-mediated agonists and stimulation of C3bi receptor expression and adherence.
Blood
74:2144, 1989[Abstract/Free Full Text]
2.
Yuo A, Kitagawa S, Ohsaka A, Saito M, Takaku F:
Stimulation and priming of human neutrophils by granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor: Qualitative and quantitative differences.
Biochem Biophys Res Commun
171:491, 1990[Medline]
[Order article via Infotrieve]
3.
Yuo A, Kitagawa S, Suzuki I, Urabe A, Okabe T, Saito M, Takaku F:
Tumor necrosis factor as an activator of human granulocytes: Potentiation of the metabolisms triggered by the Ca2+-mobilizing agonists.
J Immunol
142:1678, 1989[Abstract]
4.
Yuo A, Kitagawa S, Azuma E, Natori Y, Togawa A, Saito M, Takaku F:
Tyrosine phosphorylation and intracellular alkalinization are early events in human neutrophils stimulated by tumor necrosis factor, granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor.
Biochim Biophys Acta
1156:197, 1993[Medline]
[Order article via Infotrieve]
5.
McDonald PP, Bald A, Cassatella MA:
Activation of the NF- B pathway by inflammatory stimuli in human neutrophils.
Blood
89:3421, 1997[Abstract/Free Full Text]
6.
Burgering BMT, Bos JL:
Regulation of Ras-mediated signalling: More than one way to skin a cat.
Trends Biochem Sci
20:18, 1995[Medline]
[Order article via Infotrieve]
7.
Cano E, Mahadevan LC:
Parallel signal processing among mammalian MAPKs.
Trends Biochem Sci
20:117, 1995[Medline]
[Order article via Infotrieve]
8.
Yuo A, Okuma E, Kitagawa S, Takaku F:
Tyrosine phosphorylation of p38 but not extracellular signal-regulated kinase in normal human neutrophils stimulated by tumor necrosis factor: Comparative study with granulocyte-macrophage colony-stimulating factor.
Biochem Biophys Res Commun
235:42, 1997[Medline]
[Order article via Infotrieve]
9.
Rafiee P, Lee JK, Leung C-C, Raffin TA:
TNF- induces tyrosine phosphorylation of mitogen-activated protein kinase in adherent human neutrophils.
J Immunol
154:4785, 1995[Abstract]
10.
Gomez-Cambronero J, Colasanto JM, Huang C-K, Sha'afi RI:
Direct stimulation by tyrosine phosphorylation of microtubule-associated protein (MAP) kinase activity by granulocyte-macrophage colony-stimulating factor in human neutrophils.
Biochem J
291:211, 1993
11.
Waterman WH, Sha'afi RI:
Effects of granulocyte-macrophage colony-stimulating factor and tumour necrosis factor- on tyrosine phosphorylation and activation of mitogen-activated protein kinases in human neutrophils.
Biochem J
307:39, 1995
12.
Johnson GM, Gomez-Cambronero J:
Priming of tyrosine phosphorylation in GM-CSF-stimulated adherent neutrophils.
J Leukoc Biol
57:692, 1995[Abstract]
13.
Nahas N, Molski TFP, Fernandez GA, Sha'afi RI:
Tyrosine phosphorylation and activation of a new mitogen-activated protein (MAP)-kinase cascade in human neutrophils stimulated with various agonists.
Biochem J
318:247, 1996
14.
Kitagawa S, Ohta M, Nojiri H, Kakinuma K, Saito M, Takaku F, Miura Y:
Functional maturation of membrane potential changes and superoxide-producing capacity during differentiation of human granulocytes.
J Clin Invest
73:1062, 1984
15.
Kitagawa S, Johnston RB Jr:
Relationship between membrane potential changes and superoxide-releasing capacity in resident and activated mouse peritoneal macrophages.
J Immunol
135:3417, 1985[Abstract]
16.
Raines MA, Golde DW, Daeipour M, Nel AE:
Granulocyte-macrophage colony-stimulating factor activates microtubule-associated protein 2 kinase in neutrophils via a tyrosine kinase-dependent pathway.
Blood
79:3350, 1992[Abstract/Free Full Text]
17.
Rane MJ, Carrithers SL, Arthur JM, Klein JB, McLeish KR:
Formyl peptide receptors are coupled to multiple mitogen-activated protein kinase cascades by distinct signal transduction pathways.
J Immunol
159:5070, 1997[Abstract]
18.
Nagata Y, Moriguchi T, Nishida E, Todokoro K:
Activation of p38 MAP kinase pathway by erythropoietin and interleukin-3.
Blood
90:929, 1997[Abstract/Free Full Text]
19.
Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR:
PD098059 is a specific inhibitor of the activation of mitogen-activated protein kinase in vitro and in vivo.
J Biol Chem
270:27489, 1995[Abstract/Free Full Text]
20.
Takahashi M, Kitagawa S, Masuyama J, Ikeda U, Kasahara T, Takahashi Y, Furukawa Y, Kano S, Shimada K:
Human monocyte-endothelial cell interaction induces synthesis of granulocyte-macrophage colony-stimulating factor.
Circulation
93:1185, 1996[Abstract/Free Full Text]
21.
Lee JC, Laydon JT, McDonnell PC, Gallagheer TF, Kumar S, Green D, McNulty D, Blumenthal MJ, Heys JR, Landvatter SW, Strickler JE, McLaughlin MM, Siemens IR, Fisher SM, Livi GP, White JR, Adams JL, Young PR:
A protein kinase involved in the regulation of inflammatory cytokine biosynthesis.
Nature
372:739, 1994[Medline]
[Order article via Infotrieve]
22.
Nick JA, Avdi NJ, Young SK, Knall C, Gerwins P, Johnson GL, Worthen GS:
Common and distinct intracellular signaling pathways in human neutrophils utilized by platelet activating factor and FMLP.
J Clin Invest
99:975, 1997[Medline]
[Order article via Infotrieve]
23.
Rausch O, Marshall CJ:
Tyrosine 763 of the murine granulocyte colony-stimulating factor receptor mediates ras-dependent activation of the JNK/SAPK mitogen-activated protein kinase pathway.
Mol Cell Biol
17:1170, 1997[Abstract]
24.
Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME:
Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis.
Science
270:1326, 1995[Abstract/Free Full Text]
25.
Kuroki M, O'Flaherty JT:
Differential effects of a mitogen-activated protein kinase inhibitor on human neutrophil responses to chemotactic factors.
Biochem Biophys Res Commun
232:474, 1997[Medline]
[Order article via Infotrieve]
26.
Coffer PJ, Geijsen N, M'Rabet L, Schweizer RC, Maikoe T, Raaijmakers JAM, Lammers J-WJ, Koenderman L:
Comparison of the roles of mitogen-activated protein kinase and phosphatidylinositol 3-kinase signal transduction in neutrophil effector function.
Biochem J
329:121, 1998
27.
Yu H, Suchard SJ, Nairn R, Jove R:
Dissociation of mitogen-activated protein kinase activation from the oxidative burst in differentiated HL-60 cells and human neutrophils.
J Biol Chem
270:15719, 1995[Abstract/Free Full Text]
28.
Bashey A, Healy L, Marshall CJ:
Proliferative but not nonproliferative responses to granulocyte colony-stimulating factor are associated with rapid activation of the p21ras/MAP kinase signalling pathway.
Blood
83:949, 1994[Abstract/Free Full Text]
|